Ambry

Myriad Genetics last week launched its next-generation sequencing-based hereditary cancer panel to early-access users.

In the wake of the US Supreme Court's decision to strike down Myriad Genetics' patents on isolated BRCA1 and BRCA2 gene sequences, GeneDx this week become the latest laboratory to launch sequencing-based tests for inherited cancer that include those genes.

After being sued by Myriad Genetics for allegedly infringing its patents on BRCA1 and BRCA2 gene mutation testing, Ambry Genetics pushed back this week with its own countersuit accusing Myriad of antitrust violations.

Ever since the Supreme Court struck down Myriad Genetics' patent claims on isolated BRCA1 and BRCA2 gene sequences, industry observers have breathlessly speculated whether the company would take legal action against labs challenging its decades-long reign over the BRCA genetic te

Ardy Arianpour is now senior vice president of business development at Ambry Genetics. He previously served as vice president of business development at the company. Arianpour joined Ambry in 2009 after holding several positions at Cogenics.

Following the US Supreme Court's decision two weeks ago to strike down Myriad Genetics' central patent claims to the BRCA1 and BRCA2 genes, several US genetic testing laboratories have been gearing up to snatch a piece of the BRCA testing market in this country, previously Myriad